Researchers at UC Davis Cancer Center have shed new light on this poorly understood process. In a study to be published in the Nov. 22 issue of the journal Leukemia, the researchers report that topoisomerase II inhibitors do not directly cause leukemia -- and suggest that it may be possible to prevent therapy-induced leukemia. (The study was posted online in the journal on Sept. 29.)
"There are two competing theories of how these therapy-induced leukemias arise," said Andrew Vaughan, a radiation biologist at UC Davis Cancer Center and senior author of the new study. "One is that the topoisomerase II inhibitor drugs, in combination with the topoisomerase II enzyme they target, induce random genetic changes that lead to leukemia onset. The other is that another, potentially correctable process is at work."
In the study, Vaughan and his colleagues at Loyola University and the Sacramento Veterans Administration Hospital linked what appears to be the earliest molecular event involved in the development of therapy-induced leukemia, the rearrangement of the MLL gene (a gene involved in leukemia), to factors that activate apoptosis, or programmed cell death.
"This rearrangement appears to be independent of the topoisomerase II enzyme," Vaughan said. "This suggests that another process, such as apoptosis itself, is involved."
Topoisomerase II inhibitors work by goading cancerous cells into apoptosis. Vaughan suggests that therapy-induced leukemia may occur when some cancer cells fail to complete apoptosis and instead survive in a mutated form that contains the leukemia-inducing MLL gene.
"The good news is that apoptosis is a well-understood and potentially correctable process," Vaughan said. "Through genetic or pharmacologic means, we may be able to manipulate the cells that survive chemotherapy to complete apoptosis and die -- averting the development of leukemia."
UC Davis Cancer Center is the only National Cancer Institute-designated cancer center serving the Central Valley and inland Northern California, a region the size of Pennsylvania. Its cancer research program brings together 180 scientists on three campuses: the UC Davis Medical Center campus in Sacramento, the main UC Davis campus in Davis, Calif., and Lawrence Livermore National Laboratory in Livermore, Calif.
Media Contact:
Claudia Morain, UC Davis Cancer Center: (916) 734-9023
E-mail: claudia.morain@ucdmc.ucdavis.edu
Public Affairs
UC Davis Health System
4900 Broadway, Suite 1200
Sacramento, CA 95820
Phone: (916) 734-9040
FAX: (916) 734-9066
E-mail: publicaffairs@ucdmc.ucdavis.edu
Web address: http://www.ucdmc.ucdavis.edu/newsroom
Journal
Leukemia